Albany, NY -- (SBWIRE) -- 10/31/2018 -- DelveInsight has announced the addition of the "Prurigo Nodularis-Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size Prurigo Nodularis for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and Prurigo Nodularis forecasted epidemiology from 2018 to 2027 segmented by seven major markets.

Request for sample pages

Prurigo Nodularis is a chronic condition characterized by a papulonodular pruriginous eruption of unknown aetiology. A variety of systemic conditions have been reported to be associated with prurigo nodularis. Nerve growth factor has been implicated in the pathogenesis of prurigo nodularis. Calcitonin gene-related peptide and substance P immunoreactive nerves are markedly increased in prurigo nodularis when compared with normal skin. It is a skin condition in which hard crusty lumps form on the skin that itches intensely. Factors triggering PN, and keeping it going include nervous and mental conditions, reduced function of the liver and kidneys, and skin diseases, such as eczema, bullous pemphigoid and dermatitis herpetiformis. In many patients, the true cause is never found.

PN treatment is primarily targeted at reducing itching in an effort to reduce lesions. However, it can be challenging as people with the disease may respond to treatments differently. The most commonly used treatments for PN are oral corticosteroids, corticosteroid creams, corticosteroid injections, ointments with menthol or phenol to cool and soothe itchy skin, capsaicin cream, oral antihistamines, vitamin D3 and Selective serotonin reuptake inhibitors (SSRIs).

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Drug Companies

1. Menlo Therapeutics
2. Trevi Therapeutics
3. Galderma R&D
4. Kiniksa Pharmaceuticals
And many others

Drugs covered

1. Serlopitant
2. Nalbuphine ER
3. Nemolizumab
And many others

Report Scope

The report covers a descriptive overview of the Prurigo Nodularis, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Prurigo Nodularis and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Prurigo Nodularis are provided, along with assessment of the impact new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Prurigo Nodularis market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Prurigo Nodularis market.